Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC with Cisplatin and 5-FU in Advanced HCC
NCT02967887Phase 2Unknown
- Sponsor
- CbsBioscience Inc.
- Start
- Nov 2016
- Primary completion
- Oct 2018
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132) and fluorouracil in hepatocellular carcinoma (HCC), sponsored by CbsBioscience Inc. Primary endpoint: Objective Tumor Response at 6 months. Status: unknown.
02
Drugs
Cisplatin micelle injection (HA132)fluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02967887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967887.